Bowe v. Polymedica Corp.

432 F.3d 1, 2005 U.S. App. LEXIS 27173
CourtCourt of Appeals for the First Circuit
DecidedDecember 13, 2005
Docket04-8019
StatusPublished
Cited by151 cases

This text of 432 F.3d 1 (Bowe v. Polymedica Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bowe v. Polymedica Corp., 432 F.3d 1, 2005 U.S. App. LEXIS 27173 (1st Cir. 2005).

Opinion

LIPEZ, Circuit Judge.

In this appeal pursuant to Rule 23(f) of the Federal Rules of Civil Procedure from an order certifying a class in a securities fraud case, we must decide an issue of first impression in this Circuit: the standard for determining whether a market was “efficient” when applying the fraud-on-the-market presumption of investor reliance. We also address the level of inquiry that a district court may pursue at the class-certification stage when making that efficiency determination. Defendants-Appellants PolyMedica Corporation, Liberty Medical Supply, Inc. (“Liberty”), and various officers of both companies (collectively, “PolyMedica” 1 ) argue that the district court erred in finding that common questions predominated under Rule 23(b)(3) of the Federal Rules of Civil Procedure, by determining that the market was efficient for eight months of the class period, from January 2001 through August 2001 (the “Contested Time Period”), and deeming PolyMedica’s expert evidence irrelevant to that determination. For the reasons set forth below, we vacate the district court’s order certifying the class for the Contested Time Period, and remand for further proceedings.

I.

Thomas Thuma (“Plaintiff’) is a purchaser of PolyMedica stock, who seeks to represent a class of all purchasers of PolyMedica stock from October 1998 through August 2001. 2 PolyMedica is the parent *3 company of Liberty, a seller of diabetic testing supplies. According to Plaintiff, PolyMediea reported record revenues and earnings during the class period based primarily on the growth of Liberty’s diabetic supplies business, which accounted for up to 80% of PolyMedica’s revenues. As a result of these increases in revenue and earnings, the price of PolyMedica’s stock, which traded on the NASDAQ 3 and the American Stock Exchange during the class period, increased substantially. In the consolidated complaint, filed on October 9, 2001, Plaintiff alleges that PolyMediea artificially inflated the market price of its stock by misrepresenting sales, revenues, and accounts receivable, and by issuing false press releases, causing Plaintiff and other members of the class to purchase stock at artificially inflated prices. Plaintiff further alleges that when the truth of this fraud became known, PolyMedica’s stock lost more than 80% of its value. Plaintiff seeks damages under Section 10(b) of the Securities Exchange Act of 1934, 15 U.S.C. § 78j(b) (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5, and Section 20(a) of the Exchange Act, 15 U.S.C. § 78t(a).

On January 28, 2004, following several years of litigation, Plaintiff moved for class certification pursuant to Fed.R.Civ.P. 23(a) 4 and (b)(3) 5 , asserting that common questions of law and fact predominated, based on the “fraud-on-the-market” theory. As we explain in greater detail below, under the Supreme Court’s plurality decision in Basic, Inc. v. Levinson, 485 U.S. 224, 108 S.Ct. 978, 99 L.Ed.2d 194 (1988), 6 this theory obviates the need for a plaintiff to demonstrate individualized reliance on a defendant’s misstatement by permitting a class-wide rebuttable presumption of reliance, thereby enabling a securities fraud class action to meet Rule 23(b)(3)’s commonality requirement. PolyMediea opposed the motion, arguing that the fraud- *4 on-the-market presumption of reliance was inapplicable for the Contested Time Period 7 because the market for PolyMedica stock was not “efficient” (a prerequisite for application of the presumption). Both sides submitted expert testimony in support of their respective positions.

Plaintiffs expert, Alan R. Miller, relying upon each of the five widely-accepted market-efficiency factors set forth in Cammer v. Bloom, 711 F.Supp. 1264 (D.N.J.1989), concluded that the market for PolyMedica stock was efficient. PolyMedica’s expert, Dr. Denise Neumann Martin, in turn, concluded that the Polymedica market was not efficient, based on three factors not enumerated in Cammer. A hearing on Plaintiffs motion for class certification was held on July 16, 2004. On September 7, 2004, the district court granted Plaintiffs motion to certify the class for the entire proposed class period, rejecting Dr. Martin’s evidence as not relevant to the definition of “market efficiency,” which the court derived from Basic. The court also excluded from the class those investors who participated in short-sale transactions (i.e., transactions involving the sale of a borrowed security, as further discussed below), leaving it to “able counsel [to] develop an efficient solution” for identifying short-sellers.

PolyMedica filed an interlocutory appeal from the district court’s order certifying the class pursuant to Rule 23(f), which we permitted on February 15, 2005. 8 On appeal, PolyMedica argues that the district court erred in determining that the market for PolyMedica stock was “efficient” during the Contested Time Period, and in concluding that the fraud-on-the-market presumption of reliance was therefore applicable for these months. PolyMedica further argues that the district court erred in certifying the class without a plan for identifying and excluding short-sellers from the class.

II.

A. Standard of Review

We generally review decisions granting or denying class certification under the highly deferential “abuse of discretion” standard. Smilow v. Southwestern Bell Mobile Sys., Inc., 323 F.3d 32, 37 (1st Cir.2003). Since Rule 23 contains express legal standards for class certification, “an appeal of a class certification can pose pure issues of law which are reviewed de novo,” that is, without deference to the district court. Tardiff v. Knox County, 365 F.3d 1, 4 (1st Cir.2004). “An error of law is, of course, always an abuse of discretion.” Charlesbank Equity Fund II v. Blinds To Go, Inc., 370 F.3d 151, 158 (1st Cir.2004).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

SMITH v. DESANTIS
N.D. Florida, 2025
Singh v. Bondi
Second Circuit, 2025
McHugh v. County of Tehama
E.D. California, 2021
McFadyen v. County of Tehama
E.D. California, 2021
Elliott v. County of Tehama
E.D. California, 2021
A.H. v. County of Tehama
E.D. California, 2021
Woods v. County of Tehama
E.D. California, 2021
Phommathep v. County of Tehama
E.D. California, 2021
Cardenas v. County of Tehama
E.D. California, 2021
(HC)Moore v. Sherman
E.D. California, 2020
(HC) Williams v. Kernan
E.D. California, 2020
Winkle v. Wal-Mart Stores Inc
E.D. Washington, 2020
(HC) Shorts v. Pfeiffer
E.D. California, 2020
Medoff v. CVS Caremark (RI)
2016 DNH 029 (D. New Hampshire, 2016)
Strougo v. Barclays PLC
312 F.R.D. 307 (S.D. New York, 2016)
Carpenters Pension Trust Fund v. Barclays PLC
310 F.R.D. 69 (S.D. New York, 2015)
In re Diamond Foods, Inc., Securities Litigation
295 F.R.D. 240 (N.D. California, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
432 F.3d 1, 2005 U.S. App. LEXIS 27173, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bowe-v-polymedica-corp-ca1-2005.